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Abstract 57 
  58 
DNA from primary breast cancer samples from 625 postmenopausal (UBC-TAM series) and 328 59 
premenopausal (MA12 trial) hormone receptor-positive (HR+) patients were subjected to targeted sequencing 60 
of 83 genes to determine interactions between somatic mutation and prognosis.  Independent validation of 61 
prognostic interactions was achieved using data from the METABRIC study. Previously established 62 
associations between MAP3K1 and PIK3CA with luminal A status/favorable prognosis and TP53 mutations 63 
with Luminal B/non-luminal tumors/poor prognosis were observed, validating the methodological approach.  As 64 
observed in UBC-TAM, NF1 frame-shift nonsense (FS/NS) mutations were also a METABRIC-validated poor 65 
outcome driver. For MA12, poor outcome associated with PIK3R1 mutation was also reproducible in 66 
METABRIC. DDR1 mutations were strongly associated with poor prognosis in UBC-TAM despite stringent 67 
false-discovery correction (q=0.0003). In conclusion, uncommon recurrent somatic mutations should be further 68 
explored to create a more complete explanation of the highly variable outcomes that typifies ER+ breast 69 
cancer. 70 
            71 
Introduction 72 
  73 
While recent genomic studies have provided a comprehensive catalog of genes that accumulate somatic point 74 
mutations and small insertions/deletions (indels) in estrogen receptor-positive (ER+) breast cancer, there 75 
remains considerable uncertainty as to how these newly discovered mutations relate to disease outcomes 1, 2, 3. 76 
Most genomic discovery cohorts were neither uniformly treated nor followed long enough. For ER+ disease in 77 
particular, prognostic studies require prolonged observation since relapses often occur after 5 years 4. Uniform 78 
treatment was a feature of a whole genome sequencing study of samples accrued from a neoadjuvant 79 
aromatase inhibitor (AI) clinical trial for ER+ clinical stage 2 or 3 disease, although only short-term anti-80 
proliferative response to AI were reported. This investigation identified that mutations in MAP3K1, a tumor 81 
suppressor gene involved in stress kinase activation, were associated with indolent biological features and low 82 
proliferation rates 5. The resulting hypothesis was that MAP3K1 mutation would be associated with favorable 83 
outcomes.  In contrast, TP53 mutations associated with poor prognosis features and high proliferation rates. 84 
  85 
To more comprehensively address the relationships between somatic mutations and outcomes in ER+ breast 86 
cancer, we developed an approach to detect somatic mutations in DNA isolated from formalin fixed tumor 87 
blocks that were over 20 years old. After curating existing mutational data from breast cancer genomics 88 
discovery studies (Supplementary Data 1), 83 genes were chosen for analysis (Supplementary Table 1). We 89 
applied DNA hybrid capture, sequencing and somatic analysis to three ER+ breast cancer discovery cohorts 90 
with contrasting clinical characteristics: An older cohort treated with adjuvant tamoxifen and no chemotherapy 91 
(UBC-TAM series6), a premenopausal cohort uniformly treated with chemotherapy and randomized to 92 
tamoxifen versus observation (NCIC MA12 clinical trial7); and a third mixed cohort that was used only to 93 
expand the mutational landscape analysis (POLAR) (Supplementary Table 2). An analytical pipeline was 94 
developed to identify somatic variants while compensating for the lack of matched normal DNA, which is 95 
generally unavailable in the setting of older formalin-fixed tumor material.  Somatic mutations were analyzed 96 
for association with standard clinical variables, wherein mutated TP53 and MAP3K1 served as a priori 97 
hypotheses for poor and good outcome, respectively. Additional objectives were to identify new mutational 98 
hotspots, assess interactions with PAM50-based intrinsic subtypes and to determine mutation frequencies for 99 
therapeutic targets.  Validation was possible by comparing our results to those in cBioPortal where the genes 100 
sequenced in the METABRIC cohort overlapped with the 83 genes investigated in the study described herein. 101 
  102 
Results 103 
  104 
Sequencing and final study cohorts 105 
  106 
University of British Columbia Tamoxifen Series (UBC-TAM): These cases were drawn from a well-annotated 107 
cohort of patients treated with adjuvant tamoxifen without chemotherapy 6. A total of 625 of 632 (98.8%) patient 108 
samples that fully met study criteria passed a minimum sequencing quality cutoff of at least 80% of targeted 109 
exonic bases covered at greater than 20X (mean coverage: 133X) with other quality metrics described in the 110 
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supplementary data (Supplementary Figure 1-5 and Supplementary Data 2). Mean depth was correlated with 111 
input DNA and negatively correlated with time since diagnosis (approximate age of sample) and duplication 112 
rates were negatively correlated with input DNA and positively correlated with sample age. However, despite 113 
these trends, overall metrics were excellent with an average of 135.8X coverage and 3.0% duplicate rate 114 
despite the generally low input amounts and old sample age. The final patient population had an average age 115 
of 67 at diagnosis (range: 40-89+).  All were treated with five years of adjuvant tamoxifen, and were primarily 116 
postmenopausal, grade 2 or 3 cancers, of ductal histologic subtype (Supplementary Table 2). All were ER+ 117 
(>1% cells positive by IHC) and at least 88.6% were clinically HER2- (13/625 unknown).  A subset of 463 of 118 
these patients had PAM50 subtyping data available from a previous study 6. The median follow up in the cohort 119 
examined was 25 years and one month. 120 
  121 
NCIC-MA12 Trial cohort: These cases were drawn from a clinical trial in premenopausal women treated with a 122 
standard adjuvant chemotherapy regimen and randomized to tamoxifen versus observation. A total of 459 123 
patient samples passed the minimum sequencing quality threshold (mean coverage: 200X), of which 328 were 124 
hormone receptor positive (HR+; >1% cells positive for ER or PR by IHC), and only the HR+ cohort were 125 
included here for most analyses. The majority were premenopausal (mean age of 45). All patients received 126 
chemotherapy, and 48% were treated with 5 years of adjuvant tamoxifen. A subset of 255 of these patients 127 
had PAM50 subtyping data available. The median follow up in the cohort examined was 9.7 years 128 
 129 
POLAR cohort: This patient series was a case-control study of ER+ (>1% cells positive by IHC) breast tumors, 130 
175 of 194 (90.2%) patient samples passed minimum sequencing quality thresholds (mean coverage: 75X). A 131 
case was defined as any patient who relapsed during follow-up, and controls were defined as lacking relapse 132 
through a similar follow-up duration. Based on these definitions, there were 91 cases and 84 controls. Of the 133 
cases, 43 were early relapses (<5 years since diagnosis) and 48 were late relapses (>5 years). Patients were 134 
only included if they received adjuvant endocrine therapy, but chemotherapy was not an exclusion criterion, 135 
nor was menopausal status. Because the POLAR study was a case-control design, outcome data could not be 136 
easily integrated into prognostic analysis. Therefore, these cases were used in the mutation landscape and 137 
hotspot analyses only. 138 
  139 
Across the three cohorts, there were 1,259 patient samples that passed minimum sequencing quality 140 
thresholds and 1,128 of these were ER+ (UBC-TAM and POLAR) or ER and/or PgR+ (HR+) (MA12). 141 
  142 
Variant calling and filtering 143 
  144 
A total of over 62 million variants were identified in UBC-TAM. After extensive filtering against a set of nearly 145 
70,000 unmatched normal samples and manual review to eliminate common polymorphisms and false 146 
positives (see methods), 1,991 putative somatic variants were identified (0 to 26 variants per patient). A set of 147 
1,693 mutations was defined as the “non-silent” set for further analysis that excluded sequencing variants in 148 
splice regions (except proximal splice site), RNA genes (except MALAT1), UTRs, introns, and all silent 149 
mutations. Finally, a set of 408 frameshift or nonsense mutations was defined. The same filtering method was 150 
applied to both the POLAR and MA12 datasets. A total of 540 putative somatic mutations (436 non-silent, 145 151 
FS/NS) were identified in POLAR, and 2,104 (1,753 non-silent, 610 FS/NS) in MA12. Full details on these 152 
variants are included in Supplementary Data 3 and summarized for key genes in Supplementary Figure 6. 153 
  154 
Mutation landscape analysis 155 
In 1128 samples passing quality control standards, considering only non-silent mutations, 17 genes were 156 
mutated at a rate greater than 5%, and 6 at a rate greater than 10%; PIK3CA was the only gene mutated in 157 
greater than 20% of samples (Figure 1A). The order from most recurrent to least for the 10 most frequently 158 
mutated genes was: PIK3CA (41.1%), TP53 (15.5%), MLL3 (13.4%), MAP3K1 (12.0%), CDH1 (10.5%), 159 
MALAT1 (10.0%), GATA3 (9.1%), MLL2 (8.7%), ARID1A (7.2%), and BRCA2 (6.6%). This list correlates well 160 
with previously reported recurrently mutated genes. For example, the top 4 most significantly mutated (non-161 
silent) genes in the ER+ subset of TCGA breast project3 were PIK3CA (24.0%), TP53 (14.6%), GATA3 (8.6%) 162 
and MAP3K1 (6.1%). Considering METABRIC ER+ patients, the most recurrently mutated genes were PIK3CA 163 
(~46%), TP53 (~21%), GATA3, MLL3, CDH1, and MAP3K1 (all ~12-14%) demonstrating slightly higher but 164 
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very similar frequencies. The overall average non-silent mutation frequency was estimated as 1.6 per MB of 165 
coding sequence (range: 0.5 to 5.8 mutations per MB, excluding samples with no mutations called). In order to 166 
determine whether mutations in any gene pair were mutually exclusive or co-occurring in this dataset, a 167 
pairwise Chi-squared or Fisher’s exact test was performed. Mutations in PIK3CA and MAP3K1 were 168 
significantly more likely to co-occur (after BH FDR correction) in TAM dataset, and were near significance in 169 
MA12 although not after correction (p = 0.08). These results are summarized in Supplementary Data 4. 170 
  171 
Hotspot analysis 172 
  173 
As anticipated 8, mutations in PIK3CA at E542K, E545K, and H1047R were highly recurrent in this study with 174 
69/1259 (5.5%) E542K, 104 (8.3%) E545K, and 181 (14.4%) H1047R mutations (Supplementary Figure 6C). 175 
Mutations in the ligand binding domain of ESR1 (1.1%) were extremely rare 3, 9, 10 (Supplementary Figure 6A). 176 
To uncover novel hotspots in these data, both Chi-squared and Fisher’s exact tests were performed using 177 
mutation frequencies from previous sequencing studies as the expected values (see Methods for definition of 178 
multi-study MAF file) (Supplementary Table 3). The most notable novel finding was in CBFB (Figure 1B). At 179 
least 6 different genomic alterations were observed in 15 patients (Supplementary Data 3) that affected the 180 
donor splice site of exon 2. Manual review of this splice site identified at least two additional patients with 181 
evidence for mutations at this location. The predicted effect of these mutations is skipping of exon 2 or 182 
alternate donor site usage, each likely resulting in loss-of-function of the CBFB protein. Additional splice site 183 
mutations were observed at the exon 2, exon 4 and exon 5 acceptor sites of CBFB.  ErbB2 exhibited the 184 
anticipated profile of activating mutations from earlier publications11 with 22/1259 (1.7%) samples harboring 185 
known activating mutations and another 6 variants of unknown significance in the kinase domain or at the 186 
S310 residue (Figure 8C). 187 
  188 
Somatic mutation association with PAM50-based intrinsic subtype 189 
  190 
PAM50 intrinsic subtype calls were obtained from previously published analyses to compare to their mutational 191 
profiles for UBC-TAM and MA12 (HR+ only) studies.  In both studies about half the patients had luminal A 192 
tumors.  However, the MA12 cohort had a higher proportion of non-luminal subtypes, with 19.8% HER2-E and 193 
6.6% basal and fewer luminal B tumors (25.1% versus 42.4%) (Figure 2A-B). As expected, patients with the 194 
HER2-E intrinsic subtype were enriched for HER2+ve status compared to other subtypes (Fisher's exact test 195 
p<0.0001). Of interest, in the HER2-enriched group there were 51 tumors that were not HER2 amplified and of 196 
these 4 were HER2 mutant (∼8%), indicating that HER2 mutation could be an occasional explanation for a 197 
HER2-E subtype assignment in the absence of HER2 amplification.  For NF1 FS/NS mutations, there was also 198 
a statistically significant association with the HER2-E subtype (P=0.002) (supplementary Figure 7B, also 199 
supplementary data 5).  Notably NF1 non-silent mutations were enriched in the HER2-E non-HER2 amplified 200 
subgroup, where they were present in 8/51 cases (16%).  Compared to the frequency in all other subtypes 201 
12/582 (2%), this enrichment was significant (Fishers exact test p<0.0001) (Supplementary 7A right panel).  202 
This association could be reproduced in the METABRIC data with an NF1 non-silent mutation incidence in the 203 
HER2-E non HER2 amplified group of 8/80 (10%) versus 35/1283 (3%) in the rest of the subtypes (p=0.003) 204 
(Supplementary 7A right panel).   Age density plots by subtype serve to emphasize the large difference in the 205 
median age between the two sample cohorts (43 versus 65), and also the influence of age with respect to the 206 
intrinsic subtype incidence. Namely, in the younger MA12 cohort, there is a younger peak incidence with basal-207 
like breast cancer than Luminal A disease (Figure 2D).  In contrast in the older UBC-TAM cohort, an influence 208 
of age on intrinsic subtype was not observed (Figure 2C).   Relationships between intrinsic subtype and 209 
mutation patterns were also explored, classifying mutation positive status as “non-silent”, “missense”, 210 
nonsense/frame-shift (FS/NS) or FS/NS+splice site (Supplementary Data 5).  The FDR corrected p-value (q-211 
value) took into account that 83 genes were examined.  However, this level of false discovery detection could 212 
be viewed as overly conservative in an exploratory analysis.  Therefore, any gene mutation with q-value 213 
association of <0.2 was therefore considered reportable for the purposes of subsequent validation efforts 12, 13, 214 
14.  For MA12, non-silent TP53 mutation was highly subtype-associated because of the very high incidence in 215 
non-luminal versus luminal subtypes.  PIK3CA and MAP3K1 mutations were associated with Luminal A 216 
disease in both cohorts (Supplementary Figure 7B). Finally, there was a strong association between Luminal B 217 
status and non-silent (Supplementary Figure 7A) as well as FS/NS mutations in GATA3 (Supplementary Data 218 
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5, q value = 0.006) for MA12 (but not UBC-TAM).  GATA3 mutations were present in 28-30% of Luminal B 219 
cases and less so in luminal A cases (5%). Considering q values of <0.2 the associations between FS/NS and 220 
non-silent mutations in ATM and Luminal B tumors in MA12 (8-13%) suggests that ATM disruption is also a 221 
possible luminal B driver (Supplementary Figure 7C), at least in younger women (MA12). Relationships 222 
between age and mutation incidence were therefore also explored (Supplementary Figure 7D), with the finding 223 
that both ATM mutation and GATA3 mutations were associated with an earlier age of onset within the luminal 224 
B category (Figure 2E and 2F).  Some ATM mutations are likely to be germline (see discussion below), which 225 
could partially explain the association with younger age.   226 
 227 
Survival analysis according to somatic mutation. 228 
  229 
For the UBC-TAM Series (Figure 3A) univariate analysis, favorable prognostic associations for breast-cancer-230 
specific survival (BCSS) were detected for non-silent mutations in MAP3K1, ERBB3, XBP1 and PIK3CA 231 
(Figure 3B, Supplementary Data 6). Adverse prognostic effects were observed for non-silent mutations in 232 
DDR1 and TP53, as well as for frame-shift and nonsense (FS/NS) mutations in NF1. An analysis for 233 
recurrence free survival (RFS) produced similar results, except for ARID1B, which was marginally associated 234 
with more favorable outcome. A multivariate Cox model was applied to put each gene in the context of clinical 235 
parameters (grade, tumor size and node status).  These analyses indicated that the prognostic effects of non-236 
silent DDR1, PIK3CA, GATA3 FS/NS, TP53 and MAP3K1 mutations were independent of grade and 237 
pathological stage (Figure 3C).  Multiple correction testing, yielded DDR1 as the only gene that remained 238 
significant with a q-value of 0.0003 (Supplementary Data 5).  For the MA12 clinical trial cohort (Figure 4A) we 239 
focused on overall survival associations, as this was the primary endpoint of the study and the most robust 240 
endpoint.  A number of rarely mutated genes were associated with poor outcome in univariate analysis as 241 
displayed in Figure 4B. Multiple testing corrections indicated none of these findings could be considered 242 
significant 12, 13, 14.  However, in multivariate analysis, based on the uncorrected p value, the prognostic effects 243 
of mutations in ErbB2, ErbB4, LTK FS/NS, MAP3K4, PIK3R1, RB1, RELN and TGFB2 were independent of 244 
pathological stage and grade (Figure 4B). 245 
  246 
Verification of Prognostic effects of Mutations in METABRIC data. 247 
  248 
While few genes were significant in univariate analysis after multiple testing correction, their identification 249 
provides valuable hypotheses for further testing and validation. We therefore sought additional data in the 250 
public domain to further assess the uncorrected p value-based findings in our data set.  The METABRIC 251 
consortium have reported somatic mutations in cBioPortal 15 with co-reported detailed hormone receptor 252 
status, age at diagnosis (median age=64 years for ER+ patients), mean follow up of >8 years and disease-253 
specific (breast-cancer-specific) outcome 16, 17. This data set provided the opportunity to conduct a validation 254 
exercise for overlapping genes in the two data sets.  For the UBC-TAM series (Figure 3), 9 genes with a 255 
univariate p value of <0.05 were brought forward for validation (Figure 5).  Of the 6 overlapping genes also 256 
examined in METABRIC, consistent prognostic effects independent of clinical variables were observed for non-257 
silent mutations in three genes, MAP3K1 (favorable), TP53 (unfavorable) and NF1 FS/NS mutations 258 
(unfavorable).  In order to maintain coherence in discovery and validation patient cohorts, a similar analysis 259 
was carried out restricting the patient pool to postmenopausal patients only. No significant variation in hazard 260 
ratio for candidate genes where observed (Supplementary Table 4). For the MA12 series (Figure 4), 5 shared 261 
genes were identified with univariate p values of <0.05, yet only PIK3R1 mutations (non-silent or FS/NS) 262 
showed consistent adverse prognostic effects (Figure 6).  The Kaplan Meier survival plots for the consistent 263 
adverse prognostic effects of NF1 FS/NS (TAM vs METABRIC) and non-silent PIK3R1 (MA12 vs METABRIC) 264 
mutations are illustrated in Figure 7A-D. Copy number aberrations and chromosomal instability have been 265 
associated with prognosis across multiple cancer types, including ER-positive (ER+) breast cancer16, 18, 19. To 266 
gauge the confounding nature of commonly amplified genes in breast cancer, we further performed 267 
multivariate analysis on the candidate genes with cases of amplification of MYC, FGFR1, CCND1 and ERBB2 268 
(Supplementary Table 5). We did not observe a significant change in the hazard ratio reported in Figure 5B 269 
and 6B). 270 
  271 
Prognostic interactions between PIK3CA and MAP3K1. 272 
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  273 
Since PIK3CA and MAP3K1 mutations co-associate, the combined effect of non-silent mutations in these 274 
genes was examined.  Patients with tumors exhibiting both genes mutated have a more favorable clinical 275 
course than either singly mutant cases or cases without either gene mutated.  While the prognostic effects 276 
were strongest in the UBC-TAM series, this result was also reproduced in the METABRIC data (Figure 7E-F). 277 
  278 
Mutation Analyses for Uncommon Targetable Kinases. 279 
  280 
Of the 83 genes analyzed, at least 8 are directly targetable with small molecules or antibodies that are either 281 
FDA approved or in late-stage development (Figure 8).  Pre-existing data on these mutations is summarized 282 
(Supplementary Data 7). PIK3CA is not further discussed here, since the mutation spectrum is well described 283 
and large therapeutic studies are already underway. An examination of the 23 mutations in ERbB2 revealed 284 
locations that were, as expected, clustered in 2 major domains, with 2 of 23 having extracellular domain 285 
mutations at residue 310 and 21 of 23 having kinase domain mutations between residues 755-842 11, 20.  To 286 
further investigate the preliminary finding of an adverse prognostic effect for ErbB2 mutation in the MA12 287 
series, an examination of the METABRIC data indicated that known activating mutations in ErbB2 were 288 
associated with a near significant adverse effect (HR=1.71, P=0.075) (Supplementary Figure 8).  289 
 290 
For ERBB3, 2 known-activating mutations were identified (V104L and E928A)21. The DDR1 kinase domain 291 
mutation, R776W, is possibly homologous to EGFR hot spot mutation L858R, but the remaining DDR1 variants 292 
are of unknown significance. For the mutations in JAK1, 3 of 12 are loss of function mutations (frame shift or 293 
non-sense) and the S816* mutation has been reported in a lung adenocarcinoma sequencing data set 22.  The 294 
loss of function mutations in JAK1 have been shown to associate with immunotherapy resistance 23, 24. A few 295 
mutations identified in ERBB4, MET, and PDGFRA have been previously reported but those reported here 296 
have not been functionally tested. 297 
  298 
Discussion 299 
  300 
The strength of this investigation includes the prolonged follow up, controlled adjuvant treatment and the 301 
relatively large number of genes and patients studied. Weaknesses include the lack of treatment prediction 302 
because endocrine treatment in UBC Tam was uniform but not randomized.  In MA12 the use of tamoxifen was 303 
randomized, but the numbers were too small to examine treatment interactions. The landscape of recurrently 304 
mutated genes in ER+ breast cancer observed in this study is consistent with reports where matched germline 305 
samples were available, indicating that our variant filters were effective for somatic mutation detection in a 306 
research setting. Overall, mutation frequencies were higher in our cohort (e.g., for PIK3CA, MLL3, MAP3K1) 307 
than the TCGA cohort, but were also lower for a few specific genes (e.g., TP53 and GATA3). Due to higher 308 
sequencing data coverage of recurrently mutated target genes than TCGA and the use of a different hybrid 309 
capture reagent, we were likely able to detect mutations that were missed with lower-depth exome or whole 310 
genome sequencing data. Differences in patient populations may also be a factor. Frequencies were much 311 
closer to reported values for METABRIC which also used a targeted sequencing approach. It is also possible 312 
that in some instances we overestimated somatic mutation frequency, due to the lack of matched normal 313 
samples and imperfections in our germline polymorphism filtering. In particular, a significant number of BRCA1, 314 
BRCA2, and ATM mutations are likely de novo germline mutations that we would not be able to easily 315 
distinguish from somatic mutations. Of the 117 non-silent BRCA1/2 mutations observed (from 110/1128 316 
patients across all 3 cohorts; 7 patients had two hits) 74 were observed at a VAF greater than 40% and 31 317 
were greater 60%. Additionally, of the 61 non-silent ATM mutations (from 58/1128 samples; 3 samples had 2 318 
hits) 39 had VAF greater than 40% and 18 had VAF greater than 60 (Supplementary Data 9). Variants with 319 
VAFs this high are less likely to be somatic given the general expectation of impure tumor samples and 320 
heterozygous mutations. Indeed, the VAFs for BRCA1/2 and ATM non-silent mutations (mean=46.0%) were 321 
significantly higher than for other genes (mean=36.7%, p=5.92e-09). Even when considered separately, the 322 
VAFs for BRCA1 (mean=46.6%), BRCA2 (mean=43.8%) and ATM (mean=48.2%) were significantly higher 323 
than the other genes (p=0.002, p=0.0015, and 5.27e-5 respectively). Among the BRCA1/2 variants, there were 324 
8 known pathogenic (ENIGMA expert reviewed) mutations according to a search of the BRCA Exchange 325 
database (http://brcaexchange.org, Nov 12, 2017) and another 37 assumed pathogenic (FS/NS) mutations. Of 326 
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the remaining, 4 were benign according to expert review (ENIGMA), and 8 benign, 15 likely benign and 45 327 
variants of unknown significance according to all public sources. Out of the 61 ATM variants queried in ClinVar, 328 
4 were designated as pathogenic, 3 were pathogenic/likely pathogenic, and 2 were likely pathogenic. Another 329 
7 were frameshift mutations and assumed pathogenic. Additionally, 23 variants had uncertain significance, 8 330 
variants had conflicting interpretations of pathogenicity (any combination of benign, likely benign, or uncertain 331 
significance), and the remaining 14 variants had no data. ATM variants were also queried in the Leiden Open 332 
Variation Database (LOVD) 25, which identified 1 variant that affects function (designated as likely pathogenic 333 
by ClinVar), 10 variants with unknown effect, and 1 variant that probably does not affect function (uncertain 334 
significance in ClinVar). The remaining variants had no data in LOVD.  Given these complexities the prognostic 335 
effects of somatic versus germline BRCA1/2 and ATM mutations remain unresolved, however attention should 336 
clearly be paid to therapeutic strategies for these patients. The ATM findings deserve a particular highlight 337 
because of the younger age/luminal B association and the current lack of studies devoted to this population. 338 
  339 
The discovery of a novel recurrent CBFB (core binding factor subunit beta) splice site mutation in this cohort 340 
illustrates a limitation of exome capture reagents. The affected bases in exon 2 of CBFB display reduced 341 
sequence coverage, possibly due to high GC content, in the breast TCGA exome dataset (Supplementary 342 
Figures 9-10). This site was mutated in at least 1.5% of ER+ breast cancers sequenced, bringing the overall 343 
rate of CBFB mutations to nearly 6%, which should drive further investigation of this gene in ER+ breast 344 
cancer pathogenesis. CBFB functions as a subunit in a heterodimeric core binding transcription factor that 345 
interacts with RUNX126. Consistent with this model, CBFB mutants were mutually exclusive from RUNX1 346 
mutants in this cohort with only a single sample harboring non-silent mutations in both CBFB and RUNX1. 347 
  348 
The UBC-TAM and MA12 studies revealed different lists of potentially prognostic mutations.  Prognostic effects 349 
are likely to be strongly affected by the use of systemic therapy as well as by patient age at diagnosis.  The 350 
UBC-TAM series is the simplest study to interpret from a drug resistance perspective since the only systemic 351 
therapy was tamoxifen.  Thus, the consistent adverse effect of NF1 FS/NS mutation on prognosis is intriguing 352 
as this result is consistent with results from an in vitro screen for tamoxifen resistance27.  Understanding why 353 
only FS/NS mutations predict poor outcome, rather than missense or other non-silent mutations, will require 354 
further investigation.  The association with the HER2-E, non-HER2 amplified subset with non-synonymous NF1 355 
mutations was observed in both the discovery and validation (METABRIC) data sets.  It is a logical proposition 356 
that mutations that activate RAS, like NF1 mutation, could create a tumor with a similar transcriptional 357 
phenotype as some HER2 amplified breast cancers. PIK3R1 mutation also emerged as a consistent poor 358 
prognosis mutation from the MA12 analysis, with validation in METABRIC.  The proposed favorable prognostic 359 
effects of PIK3CA mutation were observed in the UBC-TAM series, but were not found to be independent of 360 
stage and grade, and PTEN mutations were neutral. 361 
  362 
According to our validation results, NF1, PIK3R1, PIK3CA and TP53 are therefore likely to be prognostic 363 
drivers that are independent of clinical variables. In postmenopausal women treated with adjuvant endocrine 364 
therapy, DDR1, PRKDC and XBP1 should be further studied and of these DDR1 is the strongest candidate 365 
because it was significant despite strict false discovery correction. DDR1 is a collagen-binding receptor 366 
expressed in epithelial cells that stabilizes E-cadherin–mediated intracellular adhesion28. DDR1 mutations also 367 
occur in endometrial cancer29, acute leukemia30 and lung cancer31.  Loss of DDR1 (DDR1-null mice) produces 368 
hyper-proliferation and abnormal branching of mammary ducts, suggesting DDR1 is a breast tumor 369 
suppressor32. Mutations in PRKDC will potentially produce a defective ATM response/low ATM levels 33 which 370 
is interesting in the context of the finding herein that ATM mutations are a potential luminal B driver gene.  The 371 
significance of a defective ATM pathway as a cause of endocrine resistance is highlighted by the recent finding 372 
that dysregulation of the MutL complex (MLH1, PMS1 and PMS2) causes failure of ATM/CHK2-based negative 373 
regulation of CDK4/6 34. Prognostic candidate mutations revealed by the MA12 analysis were different from the 374 
UBC TAM series, likely reflecting the different patient profiles and adjuvant treatments illustrated in Figure 2.  375 
The prognostic effects of mutations ERBB2, ERBB4, JAK1, LTK, MAP3K4, MET, PDGFRA, RB1, RELN, 376 
TGFB2, all await further study with even larger sample sizes.  377 
 378 
A limitation of this study is that the mutation datasets we generated for UBC-TAM and MA12 cohorts lack 379 
comprehensive assessment of copy number signatures that have been associated with prognosis in ER+ 380 
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breast cancer16, 18, 19. While multivariate analysis considering key CNVs did not appear to affect our prognostic 381 
associations, future studies may be needed to completely understand the interplay between simple and large-382 
scale variation for prognostic prediction. Another limitation to this study was the heterogeneity in the datasets 383 
in terms of age, treatment, and other factors that limited direct comparison and made validation with 384 
METABRIC somewhat challenging. The collection of sufficiently large, uniformly treated populations with long-385 
term follow-up for discovery and validation remains a challenge that must be addressed to fully characterize 386 
the prognostic significance of somatic mutations, especially low-frequency mutations. 387 
  388 
In conclusion, we have successfully utilized clinically well-annotated, uniformly treated patient samples using 389 
DNA from archival material greater than 20 years old without a matched normal to explore the prognostic 390 
effects encoded by the mutational landscape of ER+ breast cancer. We were able to confirm our prospective 391 
hypothesis from our earlier studies 5 that MAP3K1 is associated with indolent disease and TP53 with adverse 392 
outcomes. We also associated NF1 FS/NS mutations with strong adverse effects on prognosis. Similarly, 393 
PIK3R1 mutations were associated with an adverse prognosis, in contrast to PIK3CA mutation which were 394 
weakly favorable. This suggests somatic mutations in these two physically interacting gene products are not 395 
biologically equivalent with respect to PI3 kinase pathway activation and resistance effects.  The possibility that 396 
the long tail of low frequency mutation events in luminal type breast cancer may harbor multiple molecular 397 
explanations for poor outcomes should spur new collaborative efforts to thoroughly screen thousands of 398 
properly annotated cases.  Only after these iterative efforts of proposing and confirming candidates will a 399 
clinically useful and comprehensive somatic mutation-based classification of ER+ breast cancer emerge. In the 400 
meantime, functional studies should be pursued to understand the biological effects of low frequency somatic 401 
mutations, prioritizing these studies according to whether the mutations are driving an adverse prognostic 402 
effect and whether their disruption creates a therapeutic vulnerability.  403 
 404 
 405 
Methods 406 
 407 
For the UBC-TAM series, an institutional review board approved study was based on formalin-fixed paraffin 408 
embedded (FFPE) primary tumor blocks from 947 female patients diagnosed with estrogen receptor positive 409 
invasive breast cancer in the province of British Columbia in Canada between 1986 and 19926, 35, 36, 37.  The 410 
sample flow and analysis are provided in a REMARK summary (Figure 3A).  DNA was isolated from tumor-411 
rich regions using the Qiagen blood and tissue kit, which yielded sufficient DNA in 645 samples, of which 625 412 
met all study criteria and had sufficient sequence coverage. Similarly, approved studies provided 194 and 454 413 
HR+ patient samples for the POLAR and MA12 (Figure 4A) cohorts. A total of 175 POLAR and 459 (328 HR+) 414 
MA12 samples yielded sufficient DNA and had sufficient sequence coverage for analysis. Detailed descriptions 415 
of the patient data sets are provided in Supplementary Table 3. A meta-analysis of six existing published large-416 
scale breast cancer sequencing studies 1, 2, 3, 5, 38, 39 was performed to identify genes with recurrent coding 417 
region somatic mutations in breast cancer (Supplementary Data 1). Additional drug targets40 and genes with 418 
relevance to breast cancer from targeted sequencing41, copy-number studies16 or knowledge relating to 419 
somatic or germline mutations (e.g., BRCA1, BRCA2, ERBB2, ESR1 and PRLR) were also included. This 420 
resulted in a final list of 83 breast-cancer-related genes (Supplementary Table 1). These genes were targeted 421 
comprehensively with 3,029 complementary probes for hybridization-based enrichment (Supplementary Data 422 
8). Sequencing libraries were constructed, hybridized with capture probes, multiplexed and run on a single flow 423 
cell with up to 96 samples per pool per lane yielding approximately 375 Mb of DNA sequence per sample from 424 
an Illumina HiSeq paired end 2 X 100bp (TAM) or 2 X 125bp (POLAR, MA12) sequencing run following 425 
manufacturer's protocols. 426 
  427 
Variant calling was performed with the Genome Modeling System as previously described42. Specifically, 428 
sequence data were aligned to reference sequence build GRCh37 using BWA43 and de-duplicated with Picard. 429 
SNVs and indels were detected using the union of samtools44 and VarScan25 and annotated using Ensembl 430 
version 70. Variants were restricted to the coding regions of targeted genes and filtered for false positives and 431 
germline polymorphisms against a database of nearly 70,000 unmatched normals from the ExAC consortium45, 432 
1000 Genomes46, NHLBI exomes47 and TCGA data sets3, 48. A binomial probability model was then applied to 433 
the variants using VAF and total coverage to determine a log-likelihood ratio of being a somatic variant as 434 
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previously described49 (See Supplementary Methods). After filtering, all remaining variants were manually 435 
reviewed. To ensure that variants of known clinical relevance were not missed by automated variant calling 436 
approaches, a knowledge-based variant calling strategy was performed focused on the mutations in the 437 
Database of Curated Mutations50. 438 
  439 
Patient groups were defined by mutation status or truncating mutation status for each gene. Fisher’s exact and 440 
Chi-squared tests were used for hotspot analysis, mutual exclusivity or co-occurrence, and other categorical 441 
clinical statistics (e.g., mutation status vs. intrinsic subtype) as appropriate. Univariate Kaplan-Meier and Cox 442 
survival analyses were performed for breast-cancer-specific survival (BCSS), relapse free survival (RFS), or 443 
overall survival (OS) with non-silent or truncating mutation status as a factor. Significant survival differences 444 
between the groups were determined by log rank (Mantel-Cox) test. The Benjamini-Hochberg method was 445 
performed for multiple testing corrections to report the false discovery rate adjusted p-value (q-value). A 446 
multivariate Cox proportional hazard model was fitted to BCSS and RFS separately on gene mutation status, 447 
node status, grade and tumor size and adjusted hazard ratios were calculated with Wald test p-values. All 448 
statistical analyses were performed in the R statistical programming language with core, ‘survival’ and 449 
‘multtest’ libraries. Genomic visualizations were created with ProteinPaint51 and GenVisR52. 450 
 451 
Data Availability 452 
 453 
All mutation calls are made available as a MAF file with this publication. The raw sequence data from UBC-454 
TAM patients are available in the database of Genotypes and Phenotypes (dbGaP) under accession number 455 
[dbGAP:phsxxxx.x]. Raw sequence data from MA12 and POLAR could not be deposited in public repository 456 
due to patient consent issues and complexities of institutional certification. However, these data are available 457 
from the authors (contact Obi Griffith and Matthew Ellis). Primary clinical outcome data for UBC-TAM and 458 
MA12 can be made available to qualified researchers through application to the Canadian Cancer Trials 459 
Group. Primary clinical outcome data for POLAR can be made available to qualified researchers through 460 
application to Mitch Dowsett at the Ralph Lauren Centre for Breast Cancer Research. 461 
 462 
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Figure Legends 493 
 494 
Figure 1. Mutation recurrence and novel splice site mutation 495 
A) The overall mutation recurrence rate ranged from 41.1% of samples for PIK3CA to 0.0% for PIN1. The 496 
figure depicts non-silent mutations for all 1128 patients for the top 17 most recurrently mutated genes (>5% 497 
recurrence). If a patient had multiple mutations it is colored according to the “most damaging” mutation 498 
following the order presented in the Mutation Type legend (vertical color bar). Mutations per MB were 499 
calculated using the total number of mutations observed over the total exome space corresponding to the tiled 500 
space from “SeqCap EZ Human Exome Library v2.0”. A correction factor was applied to account for genes not 501 
assayed using the expected number of additional mutations based on ER+ TCGA data. The coverage 502 
histogram (top sidebar) shows the percent of targeted exonic bases with at least 20X, 30X and 40X coverage. 503 
B) Mutation recurrence frequencies (amino acid level) in this study were compared to previously reported 504 
mutation frequency from a multi-study MAF file of six reported breast cancer sequencing studies 505 
(Supplementary Data 1). An entirely novel mutation “hot spot” was discovered affecting the exon 2 splice 506 
(donor) site of CBFB in at least 15 patients. Six different single nucleotide substitutions, insertions and 507 
deletions were observed, all affecting either the first or second base of the donor splice site. These mutations 508 
were most likely missed in previous studies because of a lack of sequencing coverage due to the GC-rich 509 
nature of exons 1 and 2 of CBFB (Supplementary Figures 9-10). Such mutations are predicted to significantly 510 
alter the canonical donor site and result in either alternate donor usage or skipping of one or more exons of 511 
CBFB. 512 
 513 
Figure 2. Cross-cohort age and subtype analysis 514 
A-B) Percentage composition of samples by intrinsic subtype of the tumor in the two discovery cohorts for 515 
UBC-TAM (A) and MA12 (B) cohorts. C-D) Age-density plots for patients categorized by intrinsic subtype in 516 
UBC-TAM (C) and MA12 (D) cohorts. The overall median age shows that UBC-TAM is constituted mostly of 517 
post-menopausal patients (median age=65), in contrast to MA12, which has younger patients (median 518 
age=43). E-F) Younger luminal B subtype patients harbor GATA3 (E) and ATM (F) mutations in the combined 519 
set of UBC-TAM and MA12 Luminal B cases (median age=52, p=0.01; median age=58, p=0.03 for GATA3 and 520 
ATM respectively). 521 
 522 
Figure 3. Candidate discovery from UBC-TAM cohort and prognosis evaluation  523 
(A) DNA was extracted from tumor specimens from 947 patients with ER+ breast cancer treated with tamoxifen 524 
monotherapy for 5 years. 632 samples with adequate yield were sequenced for 83 genes known to be 525 
recurrently mutated or breast cancer relevant.  A total of 625 samples passed minimum quality checks and 526 
were sequenced to an average of 135.8X coverage. A total of ~62 million variants from the reference genome 527 
were identified. Extensive filtering and manual review reduced this list to 1,991 putatively somatic variants. 528 
Survival analysis was applied to non-silent and truncating gene mutation status versus disease outcome 529 
(relapse or breast-cancer-specific death). In addition, mutations were analyzed for novel hotspots, patterns of 530 
mutual exclusivity or co-occurrence and association with clinical variables. (B) Forest plot of impact of 531 
mutations in candidate genes, identified using the UBC-TAM population, on breast-cancer-specific survival 532 
(red) and recurrence-free survival (blue). The variant types are characterized based on non-silent or 533 
nonsense/frameshift (FS/NS) mutations. The box size is relative to frequency of mutations in the analysis, with 534 
larger boxes representing higher incidence mutations. (C) Multivariate forest plot of effect of mutations in UBC-535 
TAM candidate genes on breast-cancer-specific survival when assessed together with clinical factors including 536 
Tumor Grade, Node positivity and Tumor Size (>5cm). 537 
 538 
Figure 4. Candidate discovery from MA12 cohort and prognosis evaluation  539 
(A) DNA was extracted from tumor specimens and 470 samples with adequate yield were sequenced for 83 540 
genes known to be recurrently mutated or breast cancer relevant.  A total of 459 (328 HR+) samples passed 541 
minimum quality checks and were sequenced to an average of 272.6X coverage. A total of 406 million variants 542 
from the reference genome were identified. Extensive filtering and manual review reduced this list to 2104 543 
putatively somatic variants. Survival analysis was applied to non-silent and truncating gene mutation status 544 
versus overall survival. (B) Forest plot showing effect of mutation in candidate genes on overall survival 545 
(univariate - blue, multivariate - orange), along with the clinical factors used in the multivariate analysis (black), 546 
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tumor grade, node positivity and tumor size (>5cm). The box size is relative to frequency of mutations in the 547 
analysis, with larger boxes representing higher incidence mutations. Note: a few boxes are not shown if their 548 
hazard ratios were greater than 4.0. 549 
 550 
Figure 5. Validation of UBC-TAM candidates in ER+ METABRIC  551 
A) Six out of nine candidate genes from UBC-TAM analysis had mutations reported in the METABRIC cohort. 552 
1,060 ER+ samples with breast-cancer-specific survival information were used to test the effect of mutations in 553 
the candidate genes on prognosis. B) Forest plot shows effect of mutated candidate genes on breast-cancer-554 
specific survival in METABRIC ER+ cohort with univariate cox proportional-hazard ratio in blue and multivariate 555 
in orange.  The clinical factors used in the multivariate analysis, namely tumor grade, node positivity and tumor 556 
size (>5cm), are shown in black. The box size is relative to frequency of mutations in the analysis, with larger 557 
boxes representing higher incidence mutations. The # cases/CNV column shows the total number of cases 558 
with the SNV/Indel variant surrounded by a ring chart indicating the proportion of total cases with CNV 559 
alterations. 560 
 561 
Figure 6. Validation of MA12 candidates in ER+ METABRIC  562 
A) Five out of eleven candidates from MA12 analysis had mutations reported in the METABRIC cohort. 1,415 563 
ER+ samples with overall survival information were used to test the effect of mutations in the candidate genes 564 
on prognosis. B) Forest plot shows effect of mutated candidate genes, shortlisted based on MA12 mutation 565 
analysis, on overall survival in METABRIC ER+ breast cancer patients. Univariate (blue) and multivariate 566 
(orange) cox proportional-hazard ratio depict the independent prediction of survival outcomes for the six 567 
candidate genes. The box size is relative to frequency of mutations in the analysis, with larger boxes 568 
representing higher incidence mutations. The # cases/CNV column shows the total number of cases with the 569 
SNV/Indel variant surrounded by a ring chart indicating the proportion of total cases with CNV alterations. 570 
 571 
Figure 7. Kaplan-Meier plots   572 
A-B) Kaplan-Meier graphs showing the prognostic role of NF1 mutations, separated by variant type – Missense 573 
(MUT MS, green), Frameshift/Nonsense (MUT FS/NS, blue) in ER+ breast cancer patients from A) UBC-TAM 574 
and B) METABRIC cohort establishing the association between FS/NS mutations in NF1 with poor prognosis. 575 
C-D) Kaplan-Meier graph showing the prognostic role of PIK3R1 in C) MA12 and D) METABRIC ER+ breast 576 
cancer patients, categorized based on tumors with wildtype (WT, black) or mutated PIK3R1 non-silent 577 
mutations (MUT, red). E-F) Kaplan-Meier graph demonstrating co-occurrence of non-silent mutations in 578 
MAP3K1 and PIK3CA (red) in E) UBC-TAM and F) METABRIC associates with better survival when compared 579 
against tumors with mutations exclusively in MAP3K1 (blue) or PIK3CA (green) or wildtype for both MAP3K1 580 
and PIK3CA (black). p, log rank (Mantel-Cox) test p-value. 581 
 582 
Figure 8. Mutation profiles for selected genes 583 
Mutation frequency plots illustrate all non-silent mutations (TAM, POLAR, and MA12; n=1259) for 584 
representative transcripts for several kinase genes of interest. The domains belonging to A) DDR1 (RefSeq ID: 585 
NM_013994) and B) JAK1 (NM_002227) are indicated below the schematic diagram of each gene. The ECD 586 
(extracellular domain), TM (transmembrane domain), and kinase domain are depicted as green, red, and 587 
orange bars respectively for C) ERBB2 (NM_004448), D) ERBB3 (NM_001982), E) ERBB4 (NM_005235), F) 588 
MET (NM_000245), and G) PDGFRA (NM_006206). The variant counts across the three datasets for each 589 
gene are provided below the gene’s name. Note, in the mapping from Ensembl (Supplementary Data 3) to 590 
RefSeq annotations (required for use of ProteinPaint tool) a small number of variants annotations may have 591 
changed or been lost, despite selecting the most similar representative transcript possible. 592 
593 
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